Literature DB >> 28659506

Cell therapy for lung disease.

Sabine Geiger1, Daniela Hirsch2, Felix G Hermann2.   

Abstract

Besides cancer and cardiovascular diseases, lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions no effective and curative treatment options are available. Cell therapies offer a novel therapeutic approach due to their inherent anti-inflammatory and anti-fibrotic properties. Mesenchymal stem/stromal cells (MSC) are the most studied cell product. Numerous preclinical studies demonstrate an improvement of disease-associated parameters after MSC administration in several lung disorders, including chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Furthermore, results from clinical studies using MSCs for the treatment of various lung diseases indicate that MSC treatment in these patients is safe. In this review we summarise the results of preclinical and clinical studies that indicate that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless, further investigations are required.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28659506     DOI: 10.1183/16000617.0044-2017

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  23 in total

Review 1.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

Review 2.  Exploiting the potential of lung stem cells to develop pro-regenerative therapies.

Authors:  Robert E Hynds
Journal:  Biol Open       Date:  2022-10-14       Impact factor: 2.643

Review 3.  Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases.

Authors:  Yu Fujita; Tsukasa Kadota; Jun Araya; Takahiro Ochiya; Kazuyoshi Kuwano
Journal:  J Clin Med       Date:  2018-10-14       Impact factor: 4.241

4.  Predifferentiated amniotic fluid mesenchymal stem cells enhance lung alveolar epithelium regeneration and reverse elastase-induced pulmonary emphysema.

Authors:  Ying-Wei Lan; Jing-Chan Yang; Chih-Ching Yen; Tsung-Teng Huang; Ying-Cheng Chen; Hsiao-Ling Chen; Kowit-Yu Chong; Chuan-Mu Chen
Journal:  Stem Cell Res Ther       Date:  2019-06-13       Impact factor: 6.832

Review 5.  Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives.

Authors:  C Randall Harrell; Ruxana Sadikot; Jose Pascual; Crissy Fellabaum; Marina Gazdic Jankovic; Nemanja Jovicic; Valentin Djonov; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

6.  Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis.

Authors:  Feiyan Zhao; Wei Liu; Shaojie Yue; Lei Yang; Qingzhong Hua; Yan Zhou; Haipeng Cheng; Ziqiang Luo; Siyuan Tang
Journal:  Stem Cells Int       Date:  2019-01-03       Impact factor: 5.443

Review 7.  Concise Review: Therapeutic Potential of the Mesenchymal Stem Cell Derived Secretome and Extracellular Vesicles for Radiation-Induced Lung Injury: Progress and Hypotheses.

Authors:  Siguang Xu; Cong Liu; Hong-Long Ji
Journal:  Stem Cells Transl Med       Date:  2019-01-07       Impact factor: 6.940

Review 8.  Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Argyrios Tzouvelekis; Rebecca Toonkel; Theodoros Karampitsakos; Kantha Medapalli; Ioanna Ninou; Vasilis Aidinis; Demosthenes Bouros; Marilyn K Glassberg
Journal:  Front Med (Lausanne)       Date:  2018-05-15

Review 9.  Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.

Authors:  Arefeh Basiri; Zahra Pazhouhnia; Nima Beheshtizadeh; Mahdieh Hoseinpour; Amene Saghazadeh; Nima Rezaei
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 5.739

10.  Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination.

Authors:  Hong-Meng Chuang; Tina Emily Shih; Kang-Yun Lu; Sheng-Feng Tsai; Horng-Jyh Harn; Li-Ing Ho
Journal:  Cell Transplant       Date:  2018-07-11       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.